Is retroelement-based gene editing a safer alternative to CRISPR-Cas approaches?

In a Perspective, Stephen Tang and Samuel Sternberg discuss retroelement-based gene editing as a safer alternative to CRISPR-Cas approaches. Precision genome editing technologies have transformed modern biology. Capabilities for programable DNA targeting have improved rapidly, largely due to the development of bacterial RNA-guided CRISPR-Cas systems, which allow precise cleavage of target DNA sequences.

However, CRISPR-Cas9 systems generate a DNA double strand break (DSB), which activates cellular DNA repair pathways that can lead to unwanted and complex byproducts, including large chromosomal deletions and translocations, resulting in safety concerns. However, a growing body of research has shown the value of leveraging mobile genetic elements, particularly retroelements, as an alternative to CRISPR-Cas systems.

According to Tang and Sternberg, retroelements are a potentially useful tool for targeted genomic engineering because they are endogenous DNA segments that use the host's RNA polymerase to generate an RNA copy of themselves, which is then turned into complementary DNA (cDNA) by a retroelement-encoded reverse transcriptase. This cDNA product is then incorporated into the genome through a range of mechanisms that do not require DSB. Recent investigations into the structure and function of retroelement-encoded protein-RNA complexes have begun to resolve the molecular details of the mechanisms underlying these abilities, "unveiling exciting opportunities to re-engineer them for programmable DNA insertion," write the authors.

Source:
Journal reference:

Tang, S. & Sternberg, S. H., (2023) Genome editing with retroelements. Science. doi.org/10.1126/science.adi3183.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Single treatment with CRISPR gene editing therapy offers hope for hereditary angioedema patients